Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs

Takashi Kobayashi, Head, Sohyaku Innovative Research Division, Mitsubishi Tanabe Mitsubishi Tanabe Pharma aims to develop 10 late-stage (post-POC) drug candidates under its five-year plan that began in April, but the drug maker intends to do this without an increase in...read more